Bill Helman

Greylock Partners

Bill Helman is a successful venture capitalist, an expert in enterprise software, and Chair of the Investment Committee on the Dartmouth College (his undergraduate alma mater) Board of Trustees.

Helman is a Partner with Greylock, a Silicon Valley private venture capital firm that provides equity capital and supports early stage investments in technology, consumer internet and healthcare. He currently represents Greylock on the Boards of Concert Pharmaceuticals, HealthHiway, and Zipcar. As Managing Partner, he has led investments in Aveo Pharmaceuticals (Nasdaq: AVEO), Exact Sciences, Upromise (merged with Sallie Mae), OutlookSoft (merged with SAP), Tessera (merged with IXL), Ontogeny (merged with Curis), Hyperion Software (merged with Oracle), Filene’s Basement, Pharmacopeia, Millennium Pharmaceuticals (merged with Takeda), Vertex Pharmaceuticals, Mitotix (merged with GPC Biotech) and Reveal Imaging (merged with SAIC).

He also serves on the Boards of Harvard Management Company, Isabella Stewart Gardner Museum, and the Steppingstone Foundation and is an Overseer at the Museum of Fine Arts.

He holds an A.B. from Dartmouth College and an M.B.A. from Harvard Business School.